#USA #Philadelphia #Clinical Trials #Signant Health #Dr. Graham C. Ellis

Signant Health Welcomes Dr. Graham C. Ellis

In a significant move to bolster its leadership in clinical trials, Signant Health has appointed Dr. Graham C. Ellis as its Clinical Vice President. This strategic appointment, announced on April 2, 2026, aims to enhance the company’s capabilities in metabolic disease and diabetes research, areas where precise evidence generation is paramount.

A Wealth of Experience

Dr. Ellis brings over 25 years of substantial experience in the field, particularly as a specialist in diabetes, endocrinology, and metabolic diseases. He has been involved as a Principal Investigator in more than 150 international Phase 2-4 clinical studies, making him a highly valuable asset for Signant Health. His deep understanding and hands-on experience in clinical research will significantly augment the company’s prowess in managing trials related to metabolic conditions.

Commenting on his new role, Dr. Ellis stated, “I have dedicated my career to the intersection of clinical medicine and drug development. The quality of scientific evidence plays a crucial role in shaping patient outcomes. Signant's commitment to thorough evidence generation and operational expertise is uniquely tailored to support sponsors tackling the complexities of diabetes and metabolic diseases.”

Educational Background and Career Highlights

Dr. Ellis holds degrees in medical biochemistry and internal medicine from the University of Stellenbosch in South Africa. Following his education, he founded and led the HCTC, a prominent clinical research facility in his homeland. Subsequently, he held the position of Executive Director of Medical Science and Strategy at PPD, a segment of Thermo Fisher Scientific, where he oversaw a portfolio focused on diabetes and metabolic diseases. His participation in international expert panels, notably involving the GLP-1 cardiovascular outcomes trials, underscores his influence and recognition in the field.

Contributions to Signant Health

In his new position with Signant Health, Dr. Ellis will focus on enhancing the company's scientific and clinical competencies concerning metabolic disease, diabetes, obesity, and associated conditions. These therapeutic areas are becoming increasingly important due to their relevance in the pharmacological landscape and the heightened focus on regulatory oversight addressing endpoint selection and patient-reported outcomes.

His extensive investigator experience, particularly regarding large-scale multinational diabetes programs and various GLP-1 cardiovascular studies, strategically positions him to engage cooperatively with sponsor teams in crafting and executing evidence-generation methodologies.

Dawie Wessels, Signant's Chief Medical Officer, expressed enthusiasm regarding Dr. Ellis's appointment, stating, “This reflects our ongoing commitment to fortifying our scientific expertise necessary for our clients as they navigate an increasingly intricate regulatory landscape. Graham's experience as both a clinician and seasoned clinical researcher is directly applicable to the challenges sponsors face in metabolic disease and diabetes trials.”

About Signant Health

Founded over two decades ago, Signant Health stands as a leader in evidence generation, committed to leveraging technology and profound therapeutic insights to deliver high-quality evidence for diverse clinical study models. Trusted by more than 600 sponsors and contract research organizations, including all Top 20 pharmaceutical companies, Signant Health offers innovative solutions across a range of services, such as remote patient assessments, electronic data capture, and consent management.

For more information about Signant Health and their comprehensive range of evidence generation solutions, visit Signant Health.

As the demand for effective treatments in metabolic diseases continues to grow, the integration of Dr. Ellis into the Signant Health team signifies a robust step toward advancing clinical trial methodologies and outcomes.